

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Sacituzumab tirumotecan targets which of the following antigens?
 - a. B7-H3
 - b. HER2
 - c. HER3
 - d. TROP2

2. The Phase III ASCENT trial reported encouraging activity with sacituzumab govitecan in which line of therapy for patients with metastatic triple-negative breast cancer?
 - a. First line
 - b. Second line
 - c. Third line

3. Is HER2-low metastatic breast cancer more commonly ER-negative or ER-positive?
 - a. ER-negative
 - b. ER-positive
 - c. Low HER2 expression is equally common in ER-negative and ER-positive disease

4. Which of the following cases warrants the permanent discontinuation of trastuzumab deruxtecan (T-DXd)?
 - a. A patient who develops asymptomatic interstitial lung disease (ILD) that resolves after 14 days
 - b. A patient with symptomatic ILD (grade not specified)
 - c. A patient with Grade 2 ILD
 - d. Both a and c
 - e. Both b and c
 - f. All of the above cases warrant discontinuation of T-DXd

5. The Phase III DESTINY-Breast06 trial is evaluating T-DXd versus chemotherapy for patients with metastatic hormone receptor-positive breast cancer and which HER2 subtype?
 - a. HER2 positive
 - b. HER2 low
 - c. HER2 ultralow
 - d. Both a and b
 - e. Both b and c